- 11/05/2019
- EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES OUTSIDE OF JAPAN FOR EZH2 INHIBITOR TAZEMETOSTAT TO ROYALTY PHARMA
- 10/22/2019
- Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
- 10/15/2019
- NEW DRUG APPROVAL FOR FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES IN CHINA
- 09/30/2019
- EISAI AND NICHI-IKO ENTER INTO COLLABORATION AGREEMENT FOR GENERIC PHARMACEUTICAL BUSINESS IN CHINA
- 09/26/2019
- EISAI AND TOKIO MARINE NICHIDO ENTER INTO BUSINESS ALLIANCE FOR CO-EXISTENCE AND PREVENTION OF DEMENTIA
- 09/26/2019
- EISAI AND FRONTEO TO LAUNCH COROBAN® TUMBLING AND FALLING PREDICTION SYSTEM FOR INPATIENTS
- 09/24/2019
- EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO 2019 CONGRESS
- 09/20/2019
- EISAI AND MEIJI ANNOUNCE PARKINSON’S DISEASE TREATMENT EQUFINA® TABLETS (SAFINAMIDE MESILATE) APPROVED IN JAPAN
- 09/19/2019
- EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT WORLD SLEEP CONGRESS
- 09/18/2019
- FDA Approves LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
